Last Update 25 Aug 26
Fair value Decreased 13%BSX: Long-Term Pipeline Will Offset Watchman And Electrophysiology Headwinds
Analysts have reset expectations for Boston Scientific, cutting the consolidated price target to approximately $62.69 from $72.25 as they factor in reduced long term growth assumptions and a lower future P/E multiple, despite ongoing support for the stock from many firms.
Analyst Commentary
Street research on Boston Scientific now reflects a reset in expectations, but not a loss of interest in the stock. Most firms have cut price targets and trimmed longer term growth assumptions, yet many still see the company as a solid medtech holding if execution around key franchises improves.
Across the board, analysts are reacting to updated guidance, especially around Watchman and electrophysiology, and are recalibrating valuation frameworks for Boston Scientific as they factor in more conservative outlooks for 2026 and 2027.
Bullish Takeaways
- Bullish analysts highlight that Boston Scientific has continued to report Q2 results that beat revenue and EPS expectations. They view this as support for the underlying earnings base even as long term targets are revised.
- Several firms keep Buy, Overweight or Outperform ratings while cutting price targets. They signal that they still see upside potential from current levels if the company can deliver on its updated growth framework.
- Some research points to healthy procedure volumes and capital expenditure trends across medtech and to underlying fundamentals that are described as intact. This supports the case that current valuation already reflects a good amount of the recent disappointment.
- A few bullish analysts argue that recent resets to estimates and guidance may bring consensus closer to a bottom for growth and earnings expectations. They view this as a cleaner starting point for longer term minded investors.
Bearish Takeaways
- Bearish analysts focus on the reduced Watchman growth outlook, including commentary around flat sequential sales in Q2 and Q3 and workflow, clinical data and reimbursement headwinds. They see this as a key drag on Boston Scientific's growth profile and valuation.
- Several firms highlight ongoing challenges in electrophysiology and U.S. Watchman and refer to a series of estimate cuts as a concern, with one major house flagging a risk of "death by a thousand cuts" to forecasts.
- Some research stresses that 2026 and 2027 growth expectations for Boston Scientific are now more muted, with frameworks pointing to low single digit organic growth and limited EPS expansion. This supports lower P/E multiples across the medtech sector.
- A downgrade from one large broker to a more neutral stance cites near term uncertainty around key growth drivers and limited visibility on when Watchman and electrophysiology trends might stabilize. This could cap valuation until the company delivers more consistent execution.
What’s in the News for Boston Scientific
- Boston Scientific’s FARAPULSE pulsed field ablation system is gaining traction in the global atrial fibrillation treatment market, supported by regulatory clearances and adoption alongside peers such as Medtronic and Biosense Webster. Recent coverage highlights AI integration and localized manufacturing as contributors to procedural efficiency and supply resilience. Source: FARAPULSE growth article.
- The same FARAPULSE focused analysis notes that Boston Scientific’s stock price declined about 50% over the past year, while multiple valuation checks, including Discounted Cash Flow analysis in that report, indicate the shares may trade below the intrinsic value estimate used by that source. Source: FARAPULSE growth article.
- Boston Scientific has issued multiple voluntary medical device recalls tied to its FARADRIVE steerable sheaths and FARASTAR pulsed field ablation generators, largely related to air ingress risk or labeling discrepancies. These events are classified as Class II recalls and remain ongoing according to US Food and Drug Administration enforcement reports.
- The company received US Food and Drug Administration enforcement reports covering additional Class II recalls in 2026 for several CRE and Orca branded devices, as well as the TheraSphere 360 Y 90 Management Platform software, with issues ranging from potential sterile pouch breaches to a software anomaly that affects dose information in the cart.
- Boston Scientific updated its 2026 guidance and currently estimates full year 2026 net sales growth of about 5.5% to 6.5% on a reported basis. The company also guided to reported net sales growth of about 3% to 5% for the third quarter of 2026 versus the prior year period.
Valuation Changes for Boston Scientific
- Fair value has been reduced from $72.25 to $62.69, which represents a cut of around 13% in the modeled intrinsic value for Boston Scientific.
- The discount rate has moved slightly higher from 7.66% to 7.77%, which reflects a modest increase in the required return used in the valuation work.
- Revenue growth has been trimmed from 7.80% to 5.39%, which points to a more conservative long-term sales growth outlook in the updated model.
- Net profit margin has shifted from 18.89% to 18.10%, which indicates a slightly lower profitability assumption for Boston Scientific over time.
- Future P/E has been cut from 27.73x to 23.86x, which implies a lower valuation multiple assigned to the company in the revised forecasts.
29 viewsusers have viewed this narrative update
Key Takeaways
- Innovation in advanced therapies and strategic acquisitions expand market reach and support margin growth through differentiated, high-value offerings.
- Global expansion and efficiency initiatives enhance revenue diversification, improve operational margins, and drive long-term sustainable growth.
- Persistent cost pressures, competitive threats, regulatory risks, and integration challenges may limit Boston Scientific's revenue growth, pricing power, and margin resilience moving forward.
Catalysts
About Boston Scientific- Develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.
- Accelerated adoption of advanced therapies like FARAPULSE (pulsed field ablation) and WATCHMAN-backed by expanded clinical indications, strong safety/efficacy data, and increased physician uptake, particularly in major global markets-positions Boston Scientific for continued above-market procedure growth, benefiting revenue and gross margins.
- Broadening global access through double-digit growth in emerging markets, especially Asia Pacific (notably in China and Japan), supports long-term international revenue diversification and offsets potential slowdowns in developed regions, driving total top-line expansion.
- Ongoing expansion into ambulatory surgery center (ASC) settings-with regulatory changes likely to facilitate increased procedure volumes-should further boost procedure capacity for minimally invasive therapies, supporting higher recurring revenue and improving capacity constraints.
- Investment in proprietary, high-margin technologies (e.g., next-gen mapping, advanced diagnostic tools, differentiated urology/neuromodulation pipelines) combined with successful integration of recent acquisitions (Axonics, SoniVie, Intera, Silk Road) expands Boston Scientific's addressable market and is likely to drive margin expansion as product mix improves.
- Enhanced scale and operational efficiency through supply chain initiatives, digitalization, and manufacturing automation-alongside robust cash flow-positions Boston Scientific to expand operating margins and generate sustainable earnings growth over the long term.
Boston Scientific Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming Boston Scientific's revenue will grow by 5.4% annually over the next 3 years.
- Analysts assume that profit margins will increase from 17.5% today to 18.1% in 3 years time.
- Analysts expect earnings to reach $4.4 billion (and earnings per share of $2.98) by about August 2029, up from $3.7 billion today. The analysts are largely in agreement about this estimate.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 23.9x on those 2029 earnings, up from 19.3x today. This future PE is lower than the current PE for the US Medical Equipment industry at 27.4x.
- Analysts expect the number of shares outstanding to decline by 2.24% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 7.77%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- Risks to Boston Scientific's gross margin and net earnings persist due to ongoing cost headwinds from tariffs (with an expected $100 million impact in the second half of 2025) and the discontinuation of the ACURATE valve, which also signals vulnerability to product lifecycle challenges and regulatory pressures.
- Heightened competition from low-cost device manufacturers, especially in endoscopy and urology across Asia and Europe, as well as in MedSurg, risks eroding pricing power and market share, which could suppress future revenue expansion and margin resilience.
- Heavy reliance on continual product innovation and acquisition integration (e.g., Axonics, SoniVie, Intera Medical, Silk Road) introduces execution and integration risks; a failure to realize anticipated synergies or operational efficiencies may lead to margin compression and dilute overall earnings growth.
- Proposed and actual decreases in U.S. reimbursement rates (such as the 16% proposed cut in physician fee for LAA closure and pending evaluations on ASC code changes) introduce regulatory and payer risk, potentially impacting both volume (through slower adoption) and profit margins.
- Secular shifts such as increased adoption of procedures in ambulatory surgery centers (ASCs), price sensitivity in emerging markets, and accelerating healthcare consolidation may shift bargaining power to providers, thus restricting revenue growth opportunities and putting additional pressure on long-term margins and earnings.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of $62.69 for Boston Scientific based on their expectations of its future earnings growth, profit margins and other risk factors.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $94.0, and the most bearish reporting a price target of just $44.0.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $24.6 billion, earnings will come to $4.4 billion, and it would be trading on a PE ratio of 23.9x, assuming you use a discount rate of 7.8%.
- Given the current share price of $49.01, the analyst price target of $62.69 is 21.8% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Boston Scientific?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Comments
0 commentsDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Read more narratives
Boston Scientific
47.7% undervalued intrinsic discount
Pulsed Field Ablation And Minimally Invasive Therapies Will Reshape Long Term Procedure Volumes
View narrativeAN
Updated 8 Sep
Boston Scientific
1.5% undervalued intrinsic discount
Minimally Invasive Therapies And Atrial Fibrillation Treatments Will Support Steady Prospects Ahead
View narrativeAN
Updated 11 Aug
Boston Scientific
56.2% undervalued intrinsic discount
BSX after Penumbra ?
View narrativeBI
Published 25 Jan